Literature DB >> 3423749

Work capacity of patients with inflammatory joint diseases. An eight-year follow-up study.

K Kaarela1, K Lehtinen, R Luukkainen.   

Abstract

In a prospective study of recent arthritis, 103 patients had rheumatoid arthritis (RA), 63 seronegative oligoarthritis (SO), 67 reactive arthritis (REA), 20 ankylosing spondylitis (AS), and 13 psoriatic arthritis (PA). At the 8-year check-up, 36% of patients with RA were at work, compared with 69% in PA (p less than 0.002), and 85-90% in AS, SO, and REA (p less than 0.001). Correspondingly 43% of the RA patients were disabled by arthritis, compared with 23% in PA (NS), 15% in AS (p less than 0.005), none in SO, and 4% in REA (p less than 0.001). No significant differences in work capacity were noted between patients with PA, AS, SO or REA. In RA, the educational backgrounds of patients unable to work (44 patients) and able to work (37 patients) did not differ from each other or from the overall population of Finland, but a significantly (p less than 0.01) smaller number of patients with arduous work were able to continue at work. The mean age of 49 years for RA patients unable to work differed highly significantly (p less than 0.001) from the 35 years of RA patients at work. However, the weightiest cause of limited work capacity was severity of disease.

Entities:  

Mesh:

Year:  1987        PMID: 3423749     DOI: 10.3109/03009748709165410

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  8 in total

Review 1.  Combination chemotherapy in rheumatoid arthritis.

Authors:  P M Brooks; A C Schwarzer
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

2.  Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients.

Authors:  A Boonen; A Chorus; H Miedema; D van der Heijde; H van der Tempel; S van der Linden
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

3.  A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

Authors:  M J Nuijten; P Engelfriet; K Duijn; G Bruijn; D Wierz; M Koopmanschap
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Hidden psoriatic arthritis in seronegative oligoarthritis: a 14-year follow-up study.

Authors:  K Kaarela; J Mattila; K Lehtinen; A Kotaniemi; R Luukkainen
Journal:  Clin Rheumatol       Date:  1989-12       Impact factor: 2.980

5.  Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS).

Authors:  A Young; J Dixey; E Kulinskaya; N Cox; P Davies; J Devlin; P Emery; A Gough; D James; P Prouse; P Williams; J Winfield
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

Review 6.  Assessing Disease Activity in Psoriatic Arthritis: A Literature Review.

Authors:  Laura J Tucker; Laura C Coates; Philip S Helliwell
Journal:  Rheumatol Ther       Date:  2018-11-23

7.  Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores.

Authors:  Janine M Ouimet; Janet E Pope; Iris Gutmanis; John Koval
Journal:  Open Rheumatol J       Date:  2008-09-23

8.  Trends in the prevalence and incidence of ankylosing spondylitis in South Korea, 2010-2015 and estimated differences according to income status.

Authors:  Jin-Sung Park; Jae-Young Hong; Ye-Soo Park; Kyungdo Han; Seung-Woo Suh
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.